FDA Adverse Event Injury Summary report: N

REVERSE SHOULDER SYSTEM 04.01.0124 HUMERAL REVERSE HC LINER Ø39/+6MM

MDR report key: 18055001 · Received November 2, 2023

Report

Report Number
3005180920-2023-00844
Event Type
Injury
Date Received
November 2, 2023
Date of Event
October 3, 2023
Report Date
November 2, 2023
Manufacturer
MEDACTA INTERNATIONAL SA
Product Code
PHX
UDI-DI
07630040706315
PMA / PMN Number
K170452
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
US
Reporter Occupation
003

Narratives

Additional Manufacturer Narrative · 0

BATCH REVIEW PERFORMED ON 10 OCTOBER 2023: LOT 2212977: (B)(4) ITEMS MANUFACTURED AND RELEASED ON 06-SEP-2022. EXPIRATION DATE: 2027-08-16. NO ANOMALIES FOUND RELATED TO THE PROBLEM. TO DATE, (B)(4) ITEMS OF THE SAME LOT HAVE BEEN SOLD WITHOUT ANY SIMILAR REPORTED EVENT IN THE PERIOD OF REVIEW. OTHER DEVICES INVOLVED: BATCH REVIEW PERFORMED ON 10 OCTOBER 2023: LOT 2247046: (B)(4) ITEMS MANUFACTURED AND RELEASED ON 23-FEB-2023. EXPIRATION DATE: 2028-02-05. NO ANOMALIES FOUND RELATED TO THE PROBLEM. TO DATE, (B)(4) ITEMS OF THE SAME LOT HAVE BEEN SOLD WITH 2 OTHER SIMILAR REPORTED EVENTS IN THE PERIOD OF REVIEW, ONE OF THEM IS ON THE SAME IMPLANT THAT WAS NOT REVISED IN A PRECEDENT SURGERY ON THE SAME PATIENT.

Description of Event or Problem · 0

THE PATIENT HAD A PRIMARY SHOULDER SURGERY ON (B)(6) 2023. ON (B)(6) 2023, THE PATIENT CAME IN REPORTING PAIN DUE TO A DISLOCATION OF THE LINER FROM THE GLENOSPHERE. THE CAUSE OF THE DISLOCATION IS UNKNOWN. THE SURGEON REVISED THE LINER AND THE SURGERY WAS COMPLETED SUCCESSFULLY. ON (B)(6) 2023, THE PATIENT HAD A DISLOCATION OF THE LINER FROM THE GLENOSPHERE. THE SURGEON REVISED THE GLENOSPHERE, LINER, AND METAPHYSIS. THE SURGERY WAS COMPLETED SUCCESSFULLY.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1928745 REVERSE SHOULDER SYSTEM 04.01.0124 HUMERAL REVERSE HC LINER Ø39/+6MM SHOULDER HUMERAL REVERSE HC LINER PHX MEDACTA INTERNATIONAL SA 2212977 07630040706315

Patients

Seq Age Sex Outcome Treatment
1 Male Required Intervention